Literature DB >> 19812474

Parkinson disease with dementia: comparing patients with and without Alzheimer pathology.

Marwan N Sabbagh1, Charles H Adler, Tyson J Lahti, Donald J Connor, Linda Vedders, Lars K Peterson, John N Caviness, Holly A Shill, Lucia I Sue, Iryna Ziabreva, Elaine Perry, Clive G Ballard, Dag Aarsland, Douglas G Walker, Thomas G Beach.   

Abstract

Subjects with Parkinson disease (PD) frequently develop dementia with greater than one-third meeting neuropathologic diagnostic criteria for Alzheimer disease (AD). The objective is to identify clinical and neuropathologic differences between Parkinson disease with dementia (PDD) subjects, with and without coexistent AD pathology. Neuropathologic examination was available on subjects diagnosed by clinicopathologic criteria with PDD-AD (N=23) and PDD+AD (N=28). A small subset of subjects with PDD-AD and PDD+AD had received at least 1 standardized neuropsychologic assessment. PDD+AD subjects were significantly older at age of PD onset and death, progressed to onset of dementia in less time, and had a shorter duration of PD symptoms before the onset of dementia. Education, responsiveness of L-dopa and dopaminergic medications, presence of cognitive fluctuations and hallucinations, and mean Mini-Mental State Examination, Global Deterioration Scale, Functional Assessment Staging, and Unified Parkinson Disease Rating Scale scores did not differ significantly between the 2 groups. The PDD+AD group had significantly greater total plaques, neuritic plaques, total tangles, and Braak stages compared with PDD-AD. This study suggests that it is difficult to distinguish PDD+AD and PDD-AD on the basis of movement, clinical, and neuropsychologic assessment. PDD-AD and PDD+AD have similar degrees of dementia and approximately half of PDD subjects have enough AD pathology to attain a neuropathologic diagnosis of AD. PDD can develop in the absence of significant Alzheimer pathology.

Entities:  

Mesh:

Year:  2009        PMID: 19812474      PMCID: PMC2760034          DOI: 10.1097/WAD.0b013e31819c5ef4

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  10 in total

1.  Neuropathology of dementia in Parkinson's disease: a prospective, community-based study.

Authors:  Dag Aarsland; Robert Perry; Andrew Brown; Jan P Larsen; Clive Ballard
Journal:  Ann Neurol       Date:  2005-11       Impact factor: 10.422

2.  Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease?

Authors:  M N Sabbagh; N Silverberg; S Bircea; B Majeed; S Samant; J N Caviness; B Reisberg; C H Adler
Journal:  Parkinsonism Relat Disord       Date:  2005-08       Impact factor: 4.891

3.  Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections.

Authors:  H Braak; E Braak
Journal:  Brain Pathol       Date:  1991-04       Impact factor: 6.508

Review 4.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 5.  A systematic review of prevalence studies of dementia in Parkinson's disease.

Authors:  Dag Aarsland; Julia Zaccai; Carol Brayne
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

6.  Clinical phenotype of Parkinson disease dementia.

Authors:  James E Galvin; Jori Pollack; John C Morris
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

7.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

Authors:  P M Mattila; J O Rinne; H Helenius; D W Dickson; M Röyttä
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

Review 8.  Dementia associated with Parkinson's disease.

Authors:  Murat Emre
Journal:  Lancet Neurol       Date:  2003-04       Impact factor: 44.182

9.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

Authors:  Dag Aarsland; Kjeld Andersen; Jan P Larsen; Anette Lolk; Per Kragh-Sørensen
Journal:  Arch Neurol       Date:  2003-03

10.  Differences in neuropathologic characteristics across the Lewy body dementia spectrum.

Authors:  C Ballard; I Ziabreva; R Perry; J P Larsen; J O'Brien; I McKeith; E Perry; D Aarsland
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

  10 in total
  69 in total

1.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

2.  Assessing medication role on neuropathological findings in Parkinson's disease.

Authors:  Charles H Adler; Joseph G Hentz; Thomas G Beach
Journal:  Mov Disord       Date:  2016-02-16       Impact factor: 10.338

3.  Past appendectomy may be related to early cognitive dysfunction in Parkinson's disease.

Authors:  Alexandra R Gonçalves; Alexandre Mendes; Nuno Vila-Chã; Joana Damásio; Joana Fernandes; Sara M Cavaco
Journal:  Neurol Sci       Date:  2020-06-11       Impact factor: 3.307

4.  Cognitive status correlates with white matter alteration in Parkinson's disease.

Authors:  Takaaki Hattori; Satoshi Orimo; Shigeki Aoki; Kenji Ito; Osamu Abe; Atsushi Amano; Ryo Sato; Kasumi Sakai; Hidehiro Mizusawa
Journal:  Hum Brain Mapp       Date:  2011-04-14       Impact factor: 5.038

Review 5.  Association between essential tremor and other neurodegenerative diseases: what is the epidemiological evidence?

Authors:  Hiral LaRoia; Elan D Louis
Journal:  Neuroepidemiology       Date:  2011-07-13       Impact factor: 3.282

6.  Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases.

Authors:  Steven E Arnold; Jon B Toledo; Dina H Appleby; Sharon X Xie; Li-San Wang; Young Baek; David A Wolk; Edward B Lee; Bruce L Miller; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Comp Neurol       Date:  2013-12-15       Impact factor: 3.215

Review 7.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

Review 8.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

9.  Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

Authors:  Paul T Kotzbauer; Nigel J Cairns; Meghan C Campbell; Allison W Willis; Brad A Racette; Samer D Tabbal; Joel S Perlmutter
Journal:  Arch Neurol       Date:  2012-10

10.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.